Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Focus On Asia

Set Alert for Focus on Asia

Sanofi India Chief, Ex-GSK Exec On Pharma’s Digitization Journey, Tech Confluence

Sanofi India managing director N Rajaram and ex-GSK executive Salil Kallianpur discuss with Scrip a range of aspects around pharma’s digitization efforts including getting the "outside" talent mix right, avoiding digital "intrusion" in physician engagement and the impact of the surge in teleconsultation.

Commercial Digital Health

Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark

Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?

Commercial Coronavirus COVID-19

South Korea's HK inno.N Targets Cell Therapy, Vaccine Expansion Following $500m IPO

South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.

South Korea Financing

Selling More For Less In China Pays Off For AstraZeneca

Volume gains from the entry into China’s national reimbursement program offset deep price cut for AstraZeneca’s major selling Tagrisso in the second quarter of 2021.

China Sales & Earnings

New Hope, Funding Approaches As Roche Brings Evrysdi To India

Roche’s Evrysdi debuts in India backed by a patient support program ahead of Novartis’ Zolgensma and Biogen’s Spinraza. Spotlights remains on the price tag for the SMA therapy amid hopes that novel approaches such as crowdfunding could also broaden access.

Commercial Pricing Strategies

CanSino's Inhaled COVID Vaccine Shows Early Promise As Potential Booster

Early study results show CanSino’s inhaled vaccine for COVID-19 triggered an immune response similar to its injected counterpart.

Coronavirus COVID-19 Vaccines

Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change

Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.

South Korea M & A

Torrent’s Entry Into Indian Trade Generics Signals Strategy Shift

Faced with a slowdown in the US from a lack of regulatory approvals, Torrent Pharma is looking at alternate growth strategies. Its entry into the trade generics segment in India, joining other pharma majors, is one to be watched as it marks a strategic shift.

Commercial Sales & Earnings

Dr Reddy’s Gears For Sputnik Light In India, Jab For Adolescents

Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.

Commercial Coronavirus COVID-19

Novartis China Drive Paying Off, Sales Soar On Reimbursement Inclusion

Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.

China Strategy

Massive Selloff Hits US, HK-Listed China Health Cos, Clouds Sunny Prospects

Both Nasdaq- and Hong Kong-listed shares in Chinese health-related companies have been free falling with heavy volumes, after foreign investors spooked by China's general crackdown on the tech sector rushed to exit. The two-day sell-off shows high uncertainty and investors' anxiety over the regulatory overreach but underlying fundamentals still seem strong.

Financing Policy & Regulation

Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success

South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.

Deal Watch Asia Pacific
See All
UsernamePublicRestriction

Register